{
    "title": "Samsung, Biogen version of AbbVie's Humira approved in Europe",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4821772/Samsung-Biogen-version-AbbVies-Humira-approved-Europe.html",
    "date": "2017-08-25",
    "keywords": [
        "arthritis",
        "version",
        "drug",
        "humira",
        "europe",
        "year",
        "venture",
        "commission",
        "approval",
        "psoriasis",
        "crohns",
        "disease",
        "amgen",
        "johnson",
        "blockbuster",
        "union",
        "partner",
        "samsung",
        "thursday",
        "imraldi",
        "bioepis",
        "class",
        "tnf",
        "biotech",
        "momentum",
        "use",
        "business",
        "treatment",
        "juvenile",
        "spondyloarthritis",
        "plaque",
        "adult",
        "hidradenitis",
        "suppurativa",
        "colitis",
        "uveitis",
        "marketing",
        "authorization",
        "benepali",
        "incs",
        "enbrel",
        "flixabi",
        "remicade",
        "amp",
        "copy",
        "way",
        "course",
        "biogen",
        "statement",
        "company",
        "patent",
        "expiry",
        "date",
        "reference",
        "product",
        "reporting",
        "deena",
        "beasley",
        "peter",
        "cooney"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}